Methods and compositions for treating edema refractory to oral diuretics
The present invention features methods and compositions for the intranasal, sublingual, and subcutaneous administration of bumetanide for the treatment of subjects suffering from edema refractory to oral diuretics.
1 . A stable pharmaceutical composition comprising an aqueous solution comprising (a) about 0.5 to 2 percent bumetanide (wt/wt), (b) about 0.1 percent low viscosity sodium carboxymethyl cellulose (wt/wt), (c) about 0.5 percent benzyl alcohol (wt/wt), (c) about 0.078 to 0.31 percent potassium ion (wt/wt), and (d) about 2 to 4 percent mannitol (wt/wt), and wherein the aqueous solution has a pH between about 6 and about 8.
2 . The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises about 0.5 percent bumetanide (wt/wt).
3 . The pharmaceutical composition of claim 2 , wherein the pharmaceutical composition comprises about 4 percent mannitol (wt/wt).
4 . A method of treating edema in a subject, said method comprising administering to the subject a dose of from 25 μL to 250 μL of the pharmaceutical composition of claim 1 .
5 . The method of claim 4 , wherein the dose is 100 μL of the pharmaceutical composition.
6 . The method of claim 4 , wherein the dose is 200 μL of the pharmaceutical composition.
7 . The method of claim 4 , wherein the subject has congestive heart failure or renal insufficiency.
8 . The method of claim 4 , wherein the dose is delivered not more than from 1 to 4 times over a six hour period.
9 . The method of claim 4 , wherein the subject does not receive more than a total of about 10 mg of bumetanide over a 12 hour period.
10 . The method of claim 4 , wherein the subject is experiencing impaired gastrointestinal absorption of oral diuretic therapy or reduced intestinal motility prior to the administering.